<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low-dose aspirin (<z:chebi fb="0" ids="15365">acetylsalicylic acid</z:chebi>) therapy has been shown to reduce the risk of vascular events and there is increasing evidence of its potential to reduce the rate of <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> in the elderly </plain></SENT>
<SENT sid="1" pm="."><plain>Adverse effects including gastrointestinal and intracranial haemorrhage may offset these benefits </plain></SENT>
<SENT sid="2" pm="."><plain>The balance of risks versus benefits of aspirin for the primary prevention of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> has not been established in the elderly </plain></SENT>
<SENT sid="3" pm="."><plain>There is clearly a need to conduct a study in family practice to investigate whether routine use of low-dose aspirin for the primary prevention of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> in the elderly is beneficial or harmful </plain></SENT>
<SENT sid="4" pm="."><plain>Aspirin in reducing events in the elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>It will follow 15,000 subjects aged 70 years or more for an average of 5 years </plain></SENT>
<SENT sid="6" pm="."><plain>This sample size has a power of 87% to detect a 15% reduction in primary events in the aspirin group, with an anticipated combined primary event rate of 20 per 1000 patient years </plain></SENT>
</text></document>